- Biotech Express
- Articles in Magazine
- Subscription Plans
- Grow with Us
by Kamal Pratap Singh
BioAsia 2018, the flagship event of FABA and Govt. of Telangana was organized wonderfully in Hyderabad from 22-24th February. We are very happy to successfully conclude this event, said Professor Pallu Reddanna, President of FABA and Dean, School of Life Sciences, Hyderabad.
The event witnessed the presence of some great personalities like Shri Suresh Prabhu– Minister of Industries & Commerce, Govt. of India, Mr. KT Rama Rao – Minister of Industries & Commerce, Govt. of Telangana, Professor Michael Hall– Lasker Awardee, Biozentrum, University of Basel, Switzerland, Dr.Shreeram Aradhye– Chief Medical Officer, Novartis Pharma, USA, Dr.Udit Batra– Member of the Executive Board, CEO Life Science, Merck, Mr. Gregory Reh– Vice Chairman, US & Global Life, Sciences Sector Leader, Deloitte, Ms. Sangita Reddy, Joint Managing Director, Apollo Hospitals, Ms. Terri Bresenham, President and CEO, Sustainable Healthcare Solutions – GE Healthcare, Mr. Utkarsh Palnitkar, Former Life Sciences Head, KPMG India and many other notable people.
The event discusses potential of India and Hyderabad in global Pharmaceutical production as Mr. KTR rightly said that Hyderabad produces 35% of global Pharma products. The people also discussed further possibilities and setbacks in Pharma Industry growth in India. Problems in regulations were discussed with Eswara Reddy, Drugs Controller General, India who took charge as DCGI just few days back. In CEO- MEET, GV Prasad, CEO of Dr Reddy’s, Jawed Zia, Country President – India at Novartis, Philip Larsen, Global Head-Diabetes at Sanofi and few others discussed about the regulatory woes, drug companies’ growth prescription, outlook on the US market, drug discovery drive, importance of pricing freedom and many more topics concerning pharmaceutical industry.
As part of BioAsia 2018, the Genome Valley Excellence Award was given to Professor Michael N. Hall, from Biozentrum University of Basel, Switzerland, for his pioneering work in discovering the nutrient-activated TOR (Target of Rapamycin) proteins, a key element in the regulation of cell growth, which is also responsible for the development of diseases such as cancer and diabetes. Professor Hall has served at various research positions across top universities including Harvard Medical School, Frederick Cancer Research Center, University of California and University of Basel. Professor Michael N. Hall earlier received the Lasker Basic Medical Research Award 2017 – one
of the most distinguished honors in biomedical research.
Also the FABA Special Award was given to Prof. E. Premkumar Reddy, Director of Experimental Cancer Therapeutics from Mount Sinai School of Medicine, New York by Prof. Reddanna Pallu, the Executive President of FABA. Prof. Reddy was chosen for the award in recognition of his discovery of several oncogenes, which included abl, ras, fgr, mos, myb, myc and sis. Prof. Reddy, after 20 years of discovery of ras oncogene has come up with a target drug molecule, Rigosertib, which is in Phase III clinical trials, through the company founded by him-Onconova Therapeutics. Before this several multinational companies have spent more than USD 50 billion for developing drugs targeting ras oncogene, which is responsible for more than 30% of all the cancers, without a success and termed it as the “Un-druggable”. In addition to this, Dr. Reddy has developed six different cancer drugs, two of which (ON013100, and ON01210) have entered clinical trials and the other three are expected to enter clinical trials in the next one year.
Prof. Reddy after obtaining Ph.D from CCMB/Osmania University, had brief post-doctoral training at UCLA School of Medicine (1972-1974) and later served at the National Cancer Institute (1974- 84). In 1984, he moved to Hoffmann La Roche where he invented Aids Diagnostic Kit. In 1986, he joined the Wistar Institute as a Professor and Deputy Director several programs to develop vaccines for third world countries. From 1992 to 2010, he served as the Director of the Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, Philadelphia. Dr. Reddy founded the cancer journal Nature “Oncogene” in 1986 and served as its Editor from 1986 to 2009. In 2010, he founded a second cancer journal, “Genes & Cancer” for which he currently serves as the Editor-in- Chief. He is worlds highly cited author and has 300+ publications to his credit many of which are published in Nature, Science, PNAS and Cell.
This edition saw the highest ever participation of 1,757 delegates from Healthcare, Biotech, Pharma, Life-Sciences, IT, Academia and Startups representing over 52 countries with 100 high profile speakers and 500 Corporates. Around 1,250 partnering meetings were conducted on the sidelines of the event leading to key strategic decisions.
AMONG MANY ACTIVITIES BRSI CONDUCT ANNUAL CONFERENCE ON THE RECENT HOT AND EMERGING TOPICS OF BIOTECHNOLOGY THUS FACILITATE DIRECT FLOW OF INFORMATION BETWEEN GLOBAL ACADEMIES AND INDUSTRIES.
E-mail to us at: email@example.com, firstname.lastname@example.org